Serious adverse events during a 6-min walk test in patients with pulmonary hypertension

The 6-min walk test (6MWT) is well standardised and, as per current guidelines, is deemed safe to perform in a range of patients [1]. In pulmonary arterial hypertension (PAH), 6-min walk distance (6MWD) is an important predictor of mortality and morbidity [2]. Moreover, changes in the 6MWD have been the primary end-point of most pivotal randomised controlled trials that have assessed the clinical response to specific pharmacological therapies in PAH [2]. The first ever reported cases of serious adverse events during the 6MWT in patients with pulmonary hypertension The authors would like to thank Associate Professor Anne Holland (La Trobe University, Melbourne, Australia) for her comments on this manuscript.